Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC

NCT01562210 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Olaparib
DRUG: Cisplatin
RADIATION: Radiation

Sponsor

The Netherlands Cancer Institute

Collaborators

[object Object]